учитесь читать аннотации к лекарственным препаратам
... In my opinion ... 1) There are many different sources of drugs. 2) The only function of a drug is to prevent or treat diseases. 3) The drugs are dispensed on written order from a physician and over-the-counter (в свободной продаже). 4) A pharmacist must complete a Pharm. D. (Doctor of Pharmacy) afte ...
... In my opinion ... 1) There are many different sources of drugs. 2) The only function of a drug is to prevent or treat diseases. 3) The drugs are dispensed on written order from a physician and over-the-counter (в свободной продаже). 4) A pharmacist must complete a Pharm. D. (Doctor of Pharmacy) afte ...
1. Drug(s) which exhibit(s) a high hepatic" first
... Peripheral neuropathy is an expected side effect, and the patient should report any numbness or tingling of the extremities. The patient will only need to take this medication for the prescribed 14-day period. None the above What would you expect for a patient who is taking INH (isoniaside)? Urine a ...
... Peripheral neuropathy is an expected side effect, and the patient should report any numbness or tingling of the extremities. The patient will only need to take this medication for the prescribed 14-day period. None the above What would you expect for a patient who is taking INH (isoniaside)? Urine a ...
neobiocon and abraxis bioscience launch abraxane in the uae for
... integrated biotechnology company, today announced the launch of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the UAE for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant ...
... integrated biotechnology company, today announced the launch of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the UAE for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant ...
Dangers of Statin Drugs
... According to the research of Dr. Golomb, nerve problems are a common side effect from statin use; patients who use statins for two or more years are at a four to 14fold increased risk of developing idiopathic polyneuropathy compared to controls.11 She reports that in many cases, patients told her th ...
... According to the research of Dr. Golomb, nerve problems are a common side effect from statin use; patients who use statins for two or more years are at a four to 14fold increased risk of developing idiopathic polyneuropathy compared to controls.11 She reports that in many cases, patients told her th ...
- Boehringer Ingelheim (Canada)
... majority reported in elderly patients >70 years of age. If bullous pemphigoid is suspected, TRAJENTA should be discontinued. Ulcerative and necrotic skin lesions have been reported with other members of this class. Although skin lesions were not observed at an increased incidence in clinical trials, ...
... majority reported in elderly patients >70 years of age. If bullous pemphigoid is suspected, TRAJENTA should be discontinued. Ulcerative and necrotic skin lesions have been reported with other members of this class. Although skin lesions were not observed at an increased incidence in clinical trials, ...
Session 4 Topics Need to Monitor Aspirin Therapy
... Taking wrong drug Interference by other drugs – ibuprofen Polymorphisms of platelet binding sites Inadequate dose ...
... Taking wrong drug Interference by other drugs – ibuprofen Polymorphisms of platelet binding sites Inadequate dose ...
Pregabalin (Lyrica™) - A new treatment option for neuropathic pain
... rash. The superior efficacy of pregabalin (150-600 mg/day) over placebo was apparent by the first week of treatment and was sustained for the duration of each study.2 Precautions • General The safety and efficacy of pregabalin has not been established in children below the age of 18 years. Patients ...
... rash. The superior efficacy of pregabalin (150-600 mg/day) over placebo was apparent by the first week of treatment and was sustained for the duration of each study.2 Precautions • General The safety and efficacy of pregabalin has not been established in children below the age of 18 years. Patients ...
A Phase I Biological Study of MG98, an Oligodeoxynucleotide
... human DNMT1 mRNA. Antisense compounds bind to mRNA by Watson-Creek base pairing and induce target downregulation through inhibition of mRNA nuclear export and translation, alteration of mRNA stability, and activation of endonucleases (e.g.., RNase H) that degrade the mRNA/ antisense duplex (15). Alt ...
... human DNMT1 mRNA. Antisense compounds bind to mRNA by Watson-Creek base pairing and induce target downregulation through inhibition of mRNA nuclear export and translation, alteration of mRNA stability, and activation of endonucleases (e.g.., RNase H) that degrade the mRNA/ antisense duplex (15). Alt ...
ISMP Medication Safety Alert
... One of themost important ways toprevent medication errors is tolearn about problems that have occurred in other organizations and tousethat information toprevent similar problems at your practicesite. To promotesuch aprocess, thefollowing selected items fromtheJuly-September 2010 issues of theISMPMe ...
... One of themost important ways toprevent medication errors is tolearn about problems that have occurred in other organizations and tousethat information toprevent similar problems at your practicesite. To promotesuch aprocess, thefollowing selected items fromtheJuly-September 2010 issues of theISMPMe ...
Rip Van Winkle Wakes Up: Development of Tuberculosis Treatment
... of therapy required to cure drug-resistant TB, and such studies will probably use a noninferiority design. A key limiting factor for all of these types of studies is the lack of study sites, particularly in settings with a high burden, that are prepared to do high-quality clinical trials. DRUGS CURR ...
... of therapy required to cure drug-resistant TB, and such studies will probably use a noninferiority design. A key limiting factor for all of these types of studies is the lack of study sites, particularly in settings with a high burden, that are prepared to do high-quality clinical trials. DRUGS CURR ...
MODULE VII
... care to patients regardless of the group, community, ethnicity or culture. Nursing does not impose values or standards on the patient. Nurses assist the patient and family in facing decisions regarding ...
... care to patients regardless of the group, community, ethnicity or culture. Nursing does not impose values or standards on the patient. Nurses assist the patient and family in facing decisions regarding ...
Clinical Insights: Opioid-sparing Pain Management in Oral
... determined that all patients had been prescribed an opioid combination analgesic.14 A median of 8 out of 20 tablets was consumed over a 7-day period to control pain.14 The study captured what happened to the leftover pills, with the most common response being “medicine cabinets.”14 Leftover opioid p ...
... determined that all patients had been prescribed an opioid combination analgesic.14 A median of 8 out of 20 tablets was consumed over a 7-day period to control pain.14 The study captured what happened to the leftover pills, with the most common response being “medicine cabinets.”14 Leftover opioid p ...
HPS2 THRIVE IJHNFM ISIFMC_position_paper FINAL REVISION
... Thus, the data cannot be confidently extrapolated to a younger population nor perhaps to females. Position The claim that HPS2-THRIVE proved that niacin induced more harm than the statin arm of the study is not supported by the data. To evaluate this paper, one must consider the participants' risk ...
... Thus, the data cannot be confidently extrapolated to a younger population nor perhaps to females. Position The claim that HPS2-THRIVE proved that niacin induced more harm than the statin arm of the study is not supported by the data. To evaluate this paper, one must consider the participants' risk ...
Full text - Antia Laboratories Inc.
... observed.15 Fifty percent of patients in the study had stable disease during ixabepilone treatment. The median PFS was 3.1 months (95% CI 2.7–4.2 months), and the median duration of response was 5.7 months.15 Taxane-naive disease. A singlearm, Phase II study evaluated the efficacy of first-line ixab ...
... observed.15 Fifty percent of patients in the study had stable disease during ixabepilone treatment. The median PFS was 3.1 months (95% CI 2.7–4.2 months), and the median duration of response was 5.7 months.15 Taxane-naive disease. A singlearm, Phase II study evaluated the efficacy of first-line ixab ...
The acute treatment of migraine
... analgesics do not always provide adequate pain relief. Some people cannot tolerate simple painkillers because of side effects or because they have other problems such as asthma, stomach ulcers, or kidney impairment. Some patients simply do not respond to them. At this stage, if at all possible avoid ...
... analgesics do not always provide adequate pain relief. Some people cannot tolerate simple painkillers because of side effects or because they have other problems such as asthma, stomach ulcers, or kidney impairment. Some patients simply do not respond to them. At this stage, if at all possible avoid ...
Agalsidase alfa: enzyme therapy for Anderson–Fabry disease
... tissues of untreated Anderson–Fabry disease patients. Its efficacy is primarily dependent on targeted delivery of sufficient enzyme to diverse cellular sites of pathology; through a routing pathway that is contingent on the requisite pattern of glycosylation and sialylation of the carbohydrate resid ...
... tissues of untreated Anderson–Fabry disease patients. Its efficacy is primarily dependent on targeted delivery of sufficient enzyme to diverse cellular sites of pathology; through a routing pathway that is contingent on the requisite pattern of glycosylation and sialylation of the carbohydrate resid ...
References
... to severe side-effects in long-term treatment, which often occurs after the usage of 600 mg twice a day in bacterial disease for >28 days and mainly includes severe haematotoxic effects (i.e. myelosuppression, anaemia, thrombocytopaenia) or polyneuropathy [1]. However, the current standards in MDR- ...
... to severe side-effects in long-term treatment, which often occurs after the usage of 600 mg twice a day in bacterial disease for >28 days and mainly includes severe haematotoxic effects (i.e. myelosuppression, anaemia, thrombocytopaenia) or polyneuropathy [1]. However, the current standards in MDR- ...
Flolan - GSK Source
... Initiate FLOLAN in a setting with adequate personnel and equipment for physiologic monitoring and emergency care. Inspect parenteral drug products for particulate matter and discoloration prior to administration whenever solution and container permit. If either particulate matter or discoloration is ...
... Initiate FLOLAN in a setting with adequate personnel and equipment for physiologic monitoring and emergency care. Inspect parenteral drug products for particulate matter and discoloration prior to administration whenever solution and container permit. If either particulate matter or discoloration is ...
Project submission form for human involvement study
... The investigators promise to ensure that there is no falsification of data when compared to the source documents. We agree to clarify any doubts or discrepancies that may arise during the data monitoring evaluation. All the findings and conclusions of the proposed project such as review of case reco ...
... The investigators promise to ensure that there is no falsification of data when compared to the source documents. We agree to clarify any doubts or discrepancies that may arise during the data monitoring evaluation. All the findings and conclusions of the proposed project such as review of case reco ...
Pharmacy bulletin 1ed 2015
... attend a minimum of 8 visits where in each visit, patients will receive medication adherence assessment, identification and management of drug related problems, medication counselling, monitoring of clinical outcomes and diabetes education from the pharmacists. ...
... attend a minimum of 8 visits where in each visit, patients will receive medication adherence assessment, identification and management of drug related problems, medication counselling, monitoring of clinical outcomes and diabetes education from the pharmacists. ...
Introduction to Toxicology
... cyanide which may be inhaled during a fire. Furthermore, drugs may be implicated as having incapacitated a victim, thereby preventing their escape from a fire. 3. Homicides – homicidal poisonings themselves, are rare – but many homicide ...
... cyanide which may be inhaled during a fire. Furthermore, drugs may be implicated as having incapacitated a victim, thereby preventing their escape from a fire. 3. Homicides – homicidal poisonings themselves, are rare – but many homicide ...
Module 1. General pharmacology. Drugs affecting peripheral and
... medicinal forms of the drugs. Connect the text with the words: drugs, drug substance, INN, trade mark, brand name, blockbuster, etc. In the example of some pharmacological groups of drugs call their chemical, pharmacotherapeutic, pharmacodynamic affiliation. Analyze annotations of drugs: indicate th ...
... medicinal forms of the drugs. Connect the text with the words: drugs, drug substance, INN, trade mark, brand name, blockbuster, etc. In the example of some pharmacological groups of drugs call their chemical, pharmacotherapeutic, pharmacodynamic affiliation. Analyze annotations of drugs: indicate th ...
HO • 5/2H2O
... phenothiazines, other tranquilizers, sedative hypnotics or other CNS depressants (including alcohol) concomitantly with hydrocodone may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced (see WARNINGS). Laboratory Interact ...
... phenothiazines, other tranquilizers, sedative hypnotics or other CNS depressants (including alcohol) concomitantly with hydrocodone may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced (see WARNINGS). Laboratory Interact ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.